Bio Stocks™

All Photos Twitter.com
$TDOC volatility halt
$LLY Expects Potential FDA Decision On Its Alzheimer's Disease Treatment Donanemab In Early 2023 twitter.com/zbiotech/statu…
$SIOX downgraded to Sell at H.C.W. I did not know they had a Sell rating over at HCW!!
$VAXX Completes Enrollment In Part B Of UB-312 Phase 1 Trial For Parkinson's Disease. An end-of-treatment analysis expected in 2H'22
USA Q1 GDP -1.4% vs 1% estimate
$TWTR an error introduced in Mar'19 resulted in an overstatement of mDAU from Q1'19 through Q4'21 🤷‍♂️
$TWTR Q1 EPS $0.90 vs. $0.03 consensus
$TMBR Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis
$PFE $0.40/share dividend.
$CVAC - we have received confirmation from the EU that the upfront payment of €450M associated with the now terminated Advanced Purchase Agreement for CVnCoV is not to be repaid.
$CCCC initiated with an Underperform at Credit Suisse. PT $10
$MRNA EUA submission will be complete next week.
$MRNA Files for Authorization of Its #COVID19 Vaccine in Young Children Six Months to Under accesswire.com/699210/Moderna…
$VIRI Completes Enrollment in Phase 2b FORTRESS Clinical Trial for Fibromyalgia. Topline Data Expected in Sep'22
$TMDX Receives FDA PMA Approval of OCS™ DCD Heart Indication
$MRK Q1 LAGEVRIO total sales $3.2B. #molnupiravir
$MRK Q1 Adj. EPS $2.14 vs. $1.83 estimate. Sales $15.9B beat $14.6B estimate. twitter.com/BioStocks/stat…
$MRK Q1 Worldwide Sales $15.9 Billion Q1 KEYTRUDA Sales ↑ 23% to $4.8B.
$LLY Q1 EPS $2.62 vs. $2.13 estimate, Sales $7.8B vs. $6.68B estimate.
$LLY Tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 prnewswire.com/news-releases/… #Semaglutide
$SQZ Receives Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
$SLDB PT lowered to $5 Piper. 🤷‍♂️a
*Amgen Says IRS Seeks $7.1 Billion in Back Taxes and Penalties $AMGN
Retweeted by Bio Stocks™
$F scaling of high-demand EVs is on track to 600K units by late 2023. $TSLA $RIVN
$VKTX completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH Expected in 2H'22. 🥱
$TDOC Q1 revenue $565M. ↑ 25% YoY
$BMRN Q1 revenue $519M vs. $507.5M estimate
$AFMD Announces Clinical Update and Trial in Progress Posters at #ASCO22 globenewswire.com/news-release/2…
$NVCN 1 for 25 reverse split, effective Friday
Retweeted by Bio Stocks™
$OPNT Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone ir.opiant.com/news-releases/…
$YMAB CEO steps down effective immediately.
$SLDB to reduce workforce by ~ 35%
R/S effective today. $NVIV 1:25 $AGRX 1:40
$PFE growth initiative scoreboard: $EPIX $10M at $6/sh (now $5.6/sh) $TRIL $25M at $10.88/sh (BO for $18.5/sh!) $FIXX $60M at $12/sh (now $1.66/sh) $CRDF $15M at $6.22/sh (now $1.4/sh) $SPRO $40M at $16.93/sh (now $5.25/sh) $ZNTL $25M at $26.21/sh Vedanta $25M
Retweeted by Bio Stocks™
$ZNTL Announces $25 Million Equity Investment from $PFE. 953,834 shares at a price of $26.21/share
$BCRX EMA Grants PRIME Designation to ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva
$CLBS Caladrius and Cend Therapeutics Announce Definitive Merger Agreement. Combined company to be renamed Lisata Therapeutic
$PFE $BHVN VYDURA (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine. businesswire.com/news/home/2022…
$BGNE Global Phase 3 Trial of PD-1 Inhibitor Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma. businesswire.com/news/home/2022…
$DCPH prices $150M offering. 5.25M shares at $10/share + 9.75M pre-funded warrants at $9.99/warrant
$FENC FDA Accepts NDA for PEDMARK. PDUFA 09/23/22
$QGEN raises FY'22 guidance 🤦‍♂️twitter.com/BioStocks/stat…6
$AGRX 1-for-40 reverse split
$VBLT Receives Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
$TWTR PT raised to $54 at Wedbush. What abt the $0.20?
$NKTX 13.33M shares offering priced at $15/share
$PTGX Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis prnewswire.com/news-releases/…
$XAIR Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022 beyondair.net/news-and-event…
$NKTX $150M offering
Twiends™ uses the Twitter™ API, displays it's logo & trademarks, and is not endorsed or certified by them. These items remain the property of Twitter. We do not sell followers, we only provide display advertising. Bots & fake accounts are not permitted on twiends. © 2009
Grow Your Twitter Free
Want To Grow Your Twitter?
We help other people find and follow you on Twitter.
Key Info:
Started in 2009
Over 6 million signups
Country targeting provided
We never auto tweet to your timeline
We never auto follow others
We actively moderate our community
Please Share
Please upgrade your browser  chrome